Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine EdurantSelf-StudyCo-Occurring Conditions
Sign In or Register to get started
You are just a few steps away from free CE credits!
1
Sign in or Register
A free account is required.
2
Study the Material
An entire Cc section, or just a few topics at a time.
3
Take the CE Quiz
5 questions covering the topics in each Cc section.
4
Claim CE Credit
Free CNE and Free CME available!
Section Navigation
Section Navigation
- Lesson 2 Overview
Opportunistic Infections: Prevention - 0%Topic 1
Background and OverviewActivities - 0%Topic 2
Pneumocystis PneumoniaActivities - 0%Topic 3
Toxoplasma EncephalitisActivities - 0%Topic 4
Disseminated Mycobacterium avium ComplexActivities - 0%Topic 5
Cryptococcal MeningitisActivities - 0%Topic 6
CytomegalovirusActivities - 0%Topic 7
HistoplasmosisActivities - 0%Topic 8
CoccidioidomycosisActivities - 0%Topic 9
Summary PointsActivities - Opportunistic Infections: Prevention CE Quiz
Opportunistic Infections: Prevention Overview
About this Lesson
Last Updated: February 3rd, 2025
CNE/CME Continuing Education
This lesson qualifies for:
View CE Notices
- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour and 1 CE contact hour (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: October 1st, 2017
CNE and CME Review: September 1st, 2023
CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE Notices
Steps to Acquire CE for this Lesson:
3
Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled Opportunistic Infections: Prevention and available until September 1st, 2023.
Learning Objectives
- Discuss recommendations for initiating primary prevention of opportunistic infections in people with HIV
- Summarize recommendations for initiating secondary prophylaxis of opportunistic infections in people with HIV
- State criteria for discontinuing primary prevention of opportunistic infections in people with HIV
- List criteria for discontinuing secondary prophylaxis of opportunistic infections in people with HIV
- Recognize potential adverse effects and contraindications for medications used for prevention of opportunistic infections
Lesson Contributors
Authors
David H. Spach, MD
David H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures:
None
Reviewers
Aley G. Kalapila, MD, PhD
Aley G. Kalapila, MD, PhD
Associate Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Grady Health System
Associate Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Grady Health System
Disclosures:
None
Lesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.